Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OCD
MCID: OBS002
MIFTS: 68

Obsessive-Compulsive Disorder (OCD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Obsessive-Compulsive Disorder

About this section

MalaCards integrated aliases for Obsessive-Compulsive Disorder:

Name: Obsessive-Compulsive Disorder 56 12 74 25 36 29 54 42 43 15 62 17 71 32
Ocd 56 74 25
Obsessive-Compulsive Disorder, Susceptibility to 56 6
Obsessive Compulsive Disorder 12 39
Anancastic Neurosis 12 25
Obsessive-Compulsive Neurosis 25
Obsessive Compulsive Behavior 71
Anankastic Neurosis 25

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant form


HPO:

31
obsessive-compulsive disorder:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10933
OMIM 56 164230
KEGG 36 H01450
ICD9CM 34 300.3
MeSH 43 D009771
NCIt 49 C88411
SNOMED-CT 67 191736004
ICD10 32 F42 F42.9
MedGen 41 C0028768
UMLS 71 C0028768 C0600104
Sources

Summaries for Obsessive-Compulsive Disorder

About this section
MedlinePlus : 42 What is obsessive-compulsive disorder (OCD)? Obsessive-compulsive disorder (OCD) is a mental disorder in which you have thoughts (obsessions) and rituals (compulsions) over and over. They interfere with your life, but you cannot control or stop them. What causes obsessive-compulsive disorder (OCD)? The cause of obsessive-compulsive disorder (OCD) is unknown. Factors such as genetics, brain biology and chemistry, and your environment may play a role. Who is at risk for obsessive-compulsive disorder (OCD)? Obsessive-compulsive disorder (OCD) usually begins when you are a teen or young adult. Boys often develop OCD at a younger age than girls. Risk factors for OCD include Family history. People with a first-degree relative (such as a parent, sibling, or child) who has OCD are at higher risk. This is especially true if the relative developed OCD as a child or teen. Brain structure and functioning. Imaging studies have shown that people with OCD have differences in certain parts of the brain. Researchers need to do more studies to understand the connection between the brain differences and OCD. Childhood trauma, such as child abuse. Some studies have found a link between trauma in childhood and OCD. More research is needed to understand this relationship better. In some cases, children may develop OCD or OCD symptoms following a streptococcal infection. This is called Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS). What are the symptoms of obsessive-compulsive disorder (OCD)? People with OCD may have symptoms of obsessions, compulsions, or both: Obsessions are repeated thoughts, urges, or mental images that cause anxiety. They may involve things such as Fear of germs or contamination Fear of losing or misplacing something Worries about harm coming towards yourself or others Unwanted forbidden thoughts involving sex or religion Aggressive thoughts towards yourself or others Needing things lined up exactly or arranged in a particular, precise way Compulsions are behaviors that you feel like you need to do over and over to try to reduce your anxiety or stop the obsessive thoughts. Some common compulsions include Excessive cleaning and/or handwashing Repeatedly checking on things, such as whether the door is locked or the oven is off Compulsive counting Ordering and arranging things in a particular, precise way Some people with OCD also have a Tourette syndrome or another tic disorder. Tics are sudden twitches, movements, or sounds that people do repeatedly. People who have tics cannot stop their body from doing these things. How is obsessive-compulsive disorder (OCD) diagnosed? The first step is to talk with your health care provider about your symptoms. Your provider should do an exam and ask you about your health history. He or she needs to make sure that a physical problem is not causing your symptoms. If it seems to be a mental problem, your provider may refer you to a mental health specialist for further evaluation or treatment. Obsessive-compulsive disorder (OCD) can sometimes be hard to diagnose. Its symptoms are like those of other mental disorders, such as anxiety disorders. It is also possible to have both OCD and another mental disorder. Not everyone who has obsessions or compulsions has OCD. Your symptoms would usually be considered OCD when you Can't control your thoughts or behaviors, even when you know that they are excessive Spend at least 1 hour a day on these thoughts or behaviors Don't get pleasure when performing the behaviors. But doing them may briefly give you relief from the anxiety that your thoughts cause. Have significant problems in your daily life because of these thoughts or behaviors What are the treatments for obsessive-compulsive disorder (OCD)? The main treatments for obsessive-compulsive disorder (OCD) are cognitive behavioral therapy, medicines, or both: Cognitive behavioral therapy (CBT) is a type of psychotherapy. It teaches you different ways of thinking, behaving, and reacting to the obsessions and compulsions. One specific type of CBT that can treat OCD is called Exposure and Response Prevention (EX/RP). EX/RP involves gradually exposing you to your fears or obsessions. You learn healthy ways to deal with the anxiety they cause. Medicines for OCD include certain types of antidepressants. If those don't work for you, your provider may suggest taking some other type of psychiatric medicine. NIH: National Institute of Mental Health

MalaCards based summary : Obsessive-Compulsive Disorder, also known as ocd, is related to trichotillomania and body dysmorphic disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Obsessive-Compulsive Disorder is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Serotonergic synapse and Dopaminergic synapse. The drugs Ethanol and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are obsessive-compulsive behavior and anxiety

Disease Ontology : 12 An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions).

Genetics Home Reference : 25 Obsessive-compulsive disorder (OCD) is a mental health condition characterized by features called obsessions and compulsions. Obsessions are intrusive thoughts, mental images, or urges to perform specific actions. While the particular obsessions vary widely, they often include fear of illness or contamination; a desire for symmetry or getting things "just right;" or intrusive thoughts involving religion, sex, or aggression. Compulsions consist of the repetitive performance of certain actions, such as checking or verifying, washing, counting, arranging, acting out specific routines, or seeking assurance. These behaviors are performed to relieve anxiety, rather than to seek pleasure as in other compulsive behaviors like gambling, eating, or sex. While almost everyone experiences obsessive feelings and compulsive behaviors occasionally or in particular contexts, in OCD they take up more than an hour a day and cause problems with work, school, or social life. People with OCD generally experience anxiety and other distress around their need to accommodate their obsessions or compulsions. About half the time, OCD becomes evident in childhood or adolescence, and most other cases appear in early adulthood. It is unusual for OCD to start after age 40. It tends to appear earlier in males, but by adulthood it is slightly more common in females. Affected individuals can experience periods when their symptoms increase or decrease in severity, but the condition usually does not go away completely. Some people with OCD have additional mental health disorders such as generalized anxiety, depression, phobias, panic disorders, or schizophrenia. OCD can also occur in people with other neurological conditions such as Tourette syndrome and similar disorders, traumatic brain injury, stroke, or dementia.

OMIM : 56 Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated to affect nearly 5 million people in the United States (Karno et al., 1988). Evidence for a strong genetic component in OCD comes from twin studies, family genetics studies, and segregation analyses, as reviewed by Alsobrook et al. (2002). Zhang et al. (2002) suggested that hoarding is likely to be an evolutionarily conserved trait that, in times of adversity, was associated with increased survival and reproductive fitness. However, extreme forms of this trait are associated with marked disability and poor response to treatment (Black et al., 1998; Mataix-Cols et al., 1999). (164230)

KEGG : 36 Obsessive-compulsive disorder (OCD) is a psychiatric disorder characterized by recurrent, intrusive and disturbing thoughts as well as by repetitive stereotypic behaviors. OCD is a complex disorder and its pathogenesis is most likely influenced by both genetic and environmental factors. Although more than 140 candidate gene studies have been conducted, the findings have been inconclusive due to small sample size and few study replications. Many studies suggest that abnormal serotonergic neurotransmission is one of the most consistent biological findings in OCD. Studies have also reported dopaminergic abnormalities in the basal ganglia and nucleus accumbens, as well as altered glutamate transmission. First line treatments for this disorder are cognitive behavioral therapy (exposure and response prevention) and selective serotonin reuptake inhibitors (SSRIs). In recent years, one of the promising novel treatment strategies developed to improve the efficacy of treatment for patients with OCD is acceptance and commitment therapy (ACT). Recent studies have suggested that age of onset is an important factor in subtyping OCD. Early-onset OCD has been proposed to be associated with greater symptom severity, a higher prevalence of tic-related disorders, a more familial form of the condition, and a greater prevalence of psychiatry disorders in first-degree relatives as compared to late-onset OCD.

PubMed Health : 62 About obsessive-compulsive disorder: We all know the worrying feeling that we have forgotten to do something, like turning off the oven or locking the door. And it might be a good idea to double-check if you aren't absolutely sure. But some people are so worried about forgetting to do something that they feel the urge to check over and over again. Compulsive urges like this may gradually come to dominate their whole life. There are different types of obsessive-compulsive disorder (OCD). Some people are so afraid of germs that they constantly wash their hands. Others can't stop counting things, cleaning their surroundings or obsessing over the same repetitive thoughts. Regardless of the kind of ritual they may have developed, people who have OCD just can't stop doing these things.

Wikipedia : 74 Obsessive-compulsive disorder (OCD) is a mental disorder in which a person feels the need to perform... more...

Sources

Related Diseases for Obsessive-Compulsive Disorder

About this section

Diseases related to Obsessive-Compulsive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 423)
# Related Disease Score Top Affiliating Genes
1 trichotillomania 34.0 SLITRK1 SLC1A1 DRD4 DRD3 DRD2
2 body dysmorphic disorder 33.9 SLITRK1 SLC6A4 SLC1A1 OXT MAOA HTR2A
3 neurotic disorder 33.8 SLC6A4 MAOA HTR2A HTR1A BDNF
4 gilles de la tourette syndrome 33.8 SLITRK1 SLC6A4 SLC6A3 SGCE MAOA HTR3A
5 fibromyalgia 33.6 SLC6A4 HTR3A HTR2A HTR1A DRD2 COMT
6 autism spectrum disorder 33.6 TPH2 SLC6A4 SLC6A3 SLC1A1 OXT MAOA
7 schizophrenia 33.5 TPH2 SLC6A4 SLC6A3 SLC1A1 OXT MAOA
8 depression 32.9 TPH2 SLC6A4 MAOA HTR2A HTR1A BDNF
9 anxiety 32.9 TPH2 SLC6A4 SLC6A3 SLC1A1 OXT MAOA
10 tic disorder 32.8 TPH2 SLITRK1 SLC6A4 SLC6A3 SLC1A1 MAOA
11 avoidant personality disorder 32.7 SLC6A4 SLC6A3 MAOA HTR1B DRD4
12 generalized anxiety disorder 32.7 SLC6A4 SLC6A3 MAOA HTR3A HTR2A HTR1A
13 eating disorder 32.7 SLC6A4 SLC6A3 HTR2A DRD3 DRD2 COMT
14 personality disorder 32.7 TPH2 SLC6A4 SLC6A3 MAOA HTR3A HTR2A
15 obsessive-compulsive personality disorder 32.6 SLITRK1 SLC6A4 HTR2A DRD3 COMT
16 social phobia 32.6 SLC6A4 OXT MAOA HTR3A HTR1A DRD2
17 panic disorder 32.6 TPH2 SLC6A4 SLC6A3 MAOA HTR3A HTR2A
18 anorexia nervosa 32.6 SLC6A4 OXT MAOA HTR2A HTR1A DRD4
19 agoraphobia 32.5 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
20 mental depression 32.5 TPH2 SLC6A4 SLC6A3 OXT MAOA HTR3A
21 major depressive disorder 32.5 TPH2 SLC6A4 SLC6A3 OXT MAOA HTR3A
22 bipolar disorder 32.4 TPH2 SLC6A4 SLC6A3 SLC1A1 MAOA HTR3A
23 schizotypal personality disorder 32.4 DRD4 DRD2 COMT
24 acute stress disorder 32.3 SLC6A4 OXT BDNF
25 post-traumatic stress disorder 32.3 SLC6A4 MAOA HTR2A HTR1A DRD2 COMT
26 mood disorder 32.3 TPH2 SLC6A4 SLC6A3 MAOA HTR3A HTR2A
27 hypochondriasis 32.3 SLITRK1 SLC6A4 HTR3A HTR2A HTR1A BDNF
28 bulimia nervosa 32.2 SLC6A4 OXT MAOA HTR3A HTR2A HTR1B
29 chronic tic disorder 32.2 SLITRK1 DRD4 DRD3 DRD2
30 alexithymia 32.2 SLC6A4 OXT HTR1A DRD2 COMT
31 movement disease 32.2 SLC6A3 SGCE DRD4 DRD3 DRD2
32 autism 32.2 TPH2 SLC6A4 SLC6A3 SLC1A1 OXT MAOA
33 pathological gambling 32.2 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD4
34 choreatic disease 32.2 SGCE DRD4 DRD3 DRD2 BDNF
35 separation anxiety disorder 32.2 SLC6A4 SLC6A3 OXT DRD4
36 dysthymic disorder 32.2 SLC6A4 MAOA HTR2A HTR1A BDNF
37 phobia, specific 32.1 SLC6A4 OXT MAOA HTR1A COMT
38 schizoaffective disorder 32.1 SLC6A4 SLC1A1 HTR2A HTR1A DRD4 DRD3
39 somatization disorder 32.1 SLC6A4 OXT HTR2A
40 psychotic disorder 32.0 TPH2 SLC6A4 SLC6A3 SLC1A1 OXT MAOA
41 kleptomania 32.0 SLITRK1 SLC6A4 MAOA HTR1A DRD4 DRD3
42 traumatic brain injury 32.0 DRD2 COMT BDNF
43 substance abuse 32.0 SLC6A4 SLC6A3 MAOA HTR2A HTR1B HTR1A
44 oppositional defiant disorder 32.0 TPH2 SLC6A4 SLC6A3 MAOA DRD4 DRD2
45 brain injury 32.0 DRD2 COMT BDNF
46 phobic disorder 32.0 SLC6A4 OXT MAOA HTR2A HTR1A DRD2
47 dystonia 31.9 SLC6A3 SGCE HTR2A DRD3 DRD2 COMT
48 sexual disorder 31.9 SLC6A4 OXT HTR3A HTR2A HTR1A DRD4
49 endogenous depression 31.9 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
50 borderline personality disorder 31.9 TPH2 SLC6A4 SLC6A3 MAOA HTR3A HTR2A

Comorbidity relations with Obsessive-Compulsive Disorder via Phenotypic Disease Network (PDN):


Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Personality Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Disorder:



Diseases related to Obsessive-Compulsive Disorder
Sources

Symptoms & Phenotypes for Obsessive-Compulsive Disorder

About this section

Human phenotypes related to Obsessive-Compulsive Disorder:

31
# Description HPO Frequency HPO Source Accession
1 obsessive-compulsive behavior 31 very rare (1%) HP:0000722
2 anxiety 31 HP:0000739
3 depressivity 31 HP:0000716
4 skin-picking 31 HP:0012166
5 collectionism 31 HP:0030212

Symptoms via clinical synopsis from OMIM:

56
Neuro:
obsessive-compulsive disorder

Clinical features from OMIM:

164230

UMLS symptoms related to Obsessive-Compulsive Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, psychiatric symptom

GenomeRNAi Phenotypes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.87 CDK20
2 Decreased viability GR00055-A-2 9.87 CDK20
3 Decreased viability GR00106-A-0 9.87 MAOA
4 Decreased viability GR00221-A-4 9.87 CDK20
5 Decreased viability GR00240-S-1 9.87 COMT
6 Decreased viability GR00249-S 9.87 COMT HIVEP1 SGCE SLC6A4
7 Decreased viability GR00342-S-1 9.87 CDK20
8 Decreased viability GR00342-S-2 9.87 CDK20
9 Decreased viability GR00342-S-3 9.87 CDK20
10 Decreased viability GR00381-A-1 9.87 HTR1A HTR3A IQCK SLC6A4
11 Decreased viability GR00381-A-3 9.87 HTR1A HTR3A SLC6A4
12 Decreased viability GR00386-A-1 9.87 COMT HIVEP1 TPH2
13 Decreased viability GR00402-S-2 9.87 HTR1A HTR3A IQCK TPH2

MGI Mouse Phenotypes related to Obsessive-Compulsive Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 BDNF COMT DRD2 DRD3 DRD4 HTR1A
2 cardiovascular system MP:0005385 10.1 COMT DRD2 DRD3 HTR1A HTR1B MAOA
3 growth/size/body region MP:0005378 10.03 BDNF CDK20 DRD2 DRD3 HTR1B HTR3A
4 homeostasis/metabolism MP:0005376 10.03 BDNF COMT DRD2 DRD3 DRD4 HTR1A
5 endocrine/exocrine gland MP:0005379 10.02 BDNF COMT DRD2 HTR1B HTR2A HTR3A
6 digestive/alimentary MP:0005381 9.91 BDNF CDK20 DRD2 DRD3 HTR2A OXT
7 nervous system MP:0003631 9.86 BDNF CDK20 COMT DRD2 DRD3 DRD4
8 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2
Sources

Drugs & Therapeutics for Obsessive-Compulsive Disorder

About this section

PubMed Health treatment related to Obsessive-Compulsive Disorder: 62

Although there's no “cure” for OCD, with good professional help the symptoms can be reduced to a tolerable level, enabling people with OCD to start leading normal lives again. People with OCD are usually advised to have psychological treatment . Cognitive behavioral therapy (CBT) in particular has been proven to be an effective treatment for OCD. In Germany, it is offered by behavioral therapists (in German: Verhaltenstherapeuten ). Medication for depression (antidepressants) may be considered in addition to CBT, or if psychological treatment isn't an option (yet). Selective serotonin re-uptake inhibitors (SSRIs) are commonly used for this purpose. Apart from these treatments , self-help is an option, for example by talking to other people with OCD in a support group. Some people like to use books or websites to learn about their obsessive-compulsive behaviors and deal with them. Others may try to manage their OCD using relaxation techniques like meditation or autogenic training.

Drugs for Obsessive-Compulsive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
3
Topiramate Approved Phase 4 97240-79-4 5284627
4
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
5
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
7
Haloperidol Approved Phase 4 52-86-8 3559
8
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
9
Norepinephrine Approved Phase 4 51-41-2 439260
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Galantamine Approved Phase 4 357-70-0 9651
12
Ondansetron Approved Phase 4 99614-02-5 4595
13
Remifentanil Approved Phase 4 132875-61-7 60815
14
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
15
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
16
Cycloserine Approved Phase 4 68-41-7 401 6234
17
Citalopram Approved Phase 4 59729-33-8 2771
18
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
19
Propranolol Approved, Investigational Phase 4 525-66-6 4946
20
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
21
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
22
Sertraline Approved Phase 4 79617-96-2 68617
23
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
24
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
25 Anti-Infective Agents Phase 4
26 Antidotes Phase 4
27 Quetiapine Fumarate Phase 4 111974-72-2
28 Antidepressive Agents, Tricyclic Phase 4
29 Central Nervous System Stimulants Phase 4
30 Hypoglycemic Agents Phase 4
31 Respiratory System Agents Phase 4
32 Antiviral Agents Phase 4
33 Expectorants Phase 4
34 N-monoacetylcystine Phase 4
35 Haloperidol decanoate Phase 4
36 Hormones Phase 4
37 calcium channel blockers Phase 4
38 Duloxetine Hydrochloride Phase 4
39 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
40 Cholinesterase Inhibitors Phase 4
41 Narcotics Phase 4
42 Anesthetics Phase 4
43 Anesthetics, General Phase 4
44 Anesthetics, Intravenous Phase 4
45 Hypnotics and Sedatives Phase 4
46 Gastrointestinal Agents Phase 4
47 Antiemetics Phase 4
48 Dermatologic Agents Phase 4
49 Adrenergic alpha-Agonists Phase 4
50 Adrenergic Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 521)
# Name Status NCT ID Phase Drugs
1 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Unknown status NCT00182520 Phase 4 Topiramate;placebo
2 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
3 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
4 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
5 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
6 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
7 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
8 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
9 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
10 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
11 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
12 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
13 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
14 Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study Completed NCT00456937 Phase 4 Escitalopram
15 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
16 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
17 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
18 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
19 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
20 A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania Completed NCT00182507 Phase 4 Olanzapine
21 Efficacy of Exposure and Response Prevention（ERP） and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Completed NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
22 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
23 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
24 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
25 Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay Completed NCT00895752 Phase 4 Riluzole
26 The Efficacy and Safety of Galantamine for Dysfunction in Bipolar Disorder Completed NCT00741598 Phase 4 Galantamine-ER;Galantamine placebo
27 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
28 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
29 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
30 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
31 Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD Recruiting NCT03993535 Phase 4 selective serotonin reuptake inhibitor
32 A 12-week Randomized Controlled Trial of Probiotic Treatment (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) vs Placebo in Adult Obsessive Compulsive Disorder Recruiting NCT02334644 Phase 4
33 Effects of Anesthesia Drugs on Neuronal Activity in the Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery Recruiting NCT03283150 Phase 4 Remifentanil;Propofol;Dexmedetomidine
34 Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline. Active, not recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
35 A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
36 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
37 Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder Active, not recruiting NCT00640133 Phase 4
38 Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS) Not yet recruiting NCT04015596 Phase 4 Naproxen Sodium
39 The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms Not yet recruiting NCT04336228 Phase 4 Escitalopram;Placebo oral tablet
40 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
41 SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
42 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
43 A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
44 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder: A Pilot Study Unknown status NCT02590445 Phase 2, Phase 3
45 Safety and Effectiveness of Capsulotomy in Refractory Obsessive-Compulsive Disorder Unknown status NCT02375152 Phase 2, Phase 3
46 Pharmacogenetics in Primary Care Psychotropics Unknown status NCT03232502 Phase 3
47 Leuprolide Acetate Suppresses Pedophilic Urges and Arousability Unknown status NCT00220350 Phase 2, Phase 3 leuprolide acetate
48 A Prospective Multicenter Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Schizophrenia Experiencing Auditory Hallucinations Unknown status NCT00564096 Phase 2, Phase 3
49 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
50 Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder. Completed NCT01807403 Phase 3

Search NIH Clinical Center for Obsessive-Compulsive Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
Paroxetine
Paroxetine Hydrochloride
Sertraline
Sertraline Hydrochloride
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: obsessive-compulsive disorder

Sources

Genetic Tests for Obsessive-Compulsive Disorder

About this section

Genetic tests related to Obsessive-Compulsive Disorder:

# Genetic test Affiliating Genes
1 Obsessive-Compulsive Disorder 29 HTR2A SLC6A4
Sources

Anatomical Context for Obsessive-Compulsive Disorder

About this section

MalaCards organs/tissues related to Obsessive-Compulsive Disorder:

40
Brain, Testes, Cortex, Skin, Subthalamic Nucleus, Prefrontal Cortex, Eye
Sources

Publications for Obsessive-Compulsive Disorder

About this section

Articles related to Obsessive-Compulsive Disorder:

(show top 50) (show all 12414)
# Title Authors PMID Year
1
5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive-compulsive disorders. 56 6 54 61
12476319 2002
2
Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. 6 56
14593431 2003
3
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. 56 54 61
16642437 2006
4
Association between the COMT locus and obsessive-compulsive disorder in females but not males. 61 54 56
11840516 2002
5
Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. 61 54 56
10331110 1999
6
5-HT2A promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder. 6 54 61
9635956 1998
7
Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. 56 54 61
9114031 1997
8
Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. 56 61 54
7524462 1994
9
Genomewide linkage analysis in Costa Rican families implicates chromosome 15q14 as a candidate region for OCD. 56 61
21691774 2011
10
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. 61 56
20418887 2010
11
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. 61 56
17713528 2007
12
Familial and sporadic subtypes of early-onset Obsessive-Compulsive disorder. 61 56
15820710 2005
13
Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. 61 56
15272418 2004
14
Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. 56 61
12116192 2002
15
Genomewide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. 56 61
11840360 2002
16
Complex segregation analysis provides compelling evidence for a major gene underlying obsessive-compulsive disorder and for heterogeneity by sex. 56 61
11058433 2000
17
Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. 61 56
10484953 1999
18
Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. 56 61
9721822 1998
19
The epidemiology of obsessive-compulsive disorder in five US communities. 61 56
3264144 1988
20
Efficacy of Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Refractory Obsessive-Compulsive Disorder: A Clinical Cohort of 70 Patients. 42 61
31906709 2020
21
Advances in the pharmacological management of obsessive-compulsive disorder in the postpartum period. 61 42
31893946 2020
22
Neurostimulation in Anxiety Disorders, Post-traumatic Stress Disorder, and Obsessive-Compulsive Disorder. 42 61
32002936 2020
23
The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. 6
15364038 2004
24
A human serotonin transporter mutation causes constitutive activation of transport activity. 6
12869649 2003
25
Serum levels of brain-derived neurotrophic factor in drug-naïve obsessive-compulsive patients: a case-control study. 54 61
19664825 2010
26
Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. 61 54
19676096 2010
27
Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. 54 61
19660554 2010
28
The role of the brain-derived neurotrophic factor (BDNF) val66met variant in the phenotypic expression of obsessive-compulsive disorder (OCD). 61 54
19219856 2009
29
In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. 54 61
19523495 2009
30
Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. 54 61
19717141 2009
31
The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description. 61 54
20098825 2009
32
Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. 61 54
18706700 2009
33
Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. 54 61
19179283 2009
34
Enhanced activity of human serotonin transporter variants associated with autism. 61 54
18957375 2009
35
Decision-making impairment is related to serotonin transporter promoter polymorphism in a sample of patients with obsessive-compulsive disorder. 61 54
18603313 2008
36
Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. 61 54
18354388 2008
37
Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. 54 61
17805313 2008
38
Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. 61 54
18186076 2008
39
The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder. 61 54
18339223 2008
40
Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease. 61 54
18490109 2008
41
Association between a common haplotype in the COMT gene region and psychiatric disorders in individuals with 22q11.2DS. 54 61
17949513 2008
42
Extensive genotyping of the BDNF and NTRK2 genes define protective haplotypes against obsessive-compulsive disorder. 54 61
17884018 2008
43
A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. 61 54
18055562 2008
44
Design of electrochemical biosensor systems for the detection of specific DNA sequences in PCR-amplified nucleic acids related to the catechol-O-methyltransferase Val108/158Met polymorphism based on intrinsic guanine signal. 54 61
18181582 2008
45
SERT Ileu425Val in autism, Asperger syndrome and obsessive-compulsive disorder. 61 54
18197083 2008
46
The role of oxytocin in neuropsychiatric disorders. 54 61
18336283 2008
47
A large case-control study of common functional SLC6A4 and BDNF variants in obsessive-compulsive disorder. 54 61
17375136 2007
48
Serotonin transporter phosphorylation by cGMP-dependent protein kinase is altered by a mutation associated with obsessive compulsive disorder. 54 61
17913921 2007
49
The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. 61 54
17264842 2007
50
Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. 54 61
17430417 2007
Sources

Variations for Obsessive-Compulsive Disorder

About this section

ClinVar genetic disease variations for Obsessive-Compulsive Disorder:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HIVEP1 NM_002114.4(HIVEP1):c.4089G>C (p.Met1363Ile)SNV Pathogenic 375377 rs776300630 6:12124117-12124117 6:12123884-12123884
2 CDK20 NM_001039803.2(CDK20):c.564G>A (p.Trp188Ter)SNV Pathogenic 375376 rs1057519438 9:90584834-90584834 9:87969919-87969919
3 HTR2A HTR2A, -1438G-ASNV risk factor 12937
4 46;XY;t(1;2)(q31.2;p15)Translocation Likely pathogenic 267880
5 46;XX;t(2;5)(q33;p15.3)Translocation Uncertain significance 267966
6 46;XY;t(2;11)(q31;q13.5)patTranslocation Uncertain significance 267865
7 SLC6A4 NM_001045.6(SLC6A4):c.1273A>G (p.Ile425Val)SNV Uncertain significance 12935 rs28914832 17:28538374-28538374 17:30211356-30211356

Copy number variations for Obsessive-Compulsive Disorder from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 77765 13 47471310 47471410 Deletion Obsessive-compulsive disorder
2 160222 22 11800000 24300000 Deletion Obsessive-compulsive disorder
Sources

Expression for Obsessive-Compulsive Disorder

About this section
Search GEO for disease gene expression data for Obsessive-Compulsive Disorder.
Sources

Pathways for Obsessive-Compulsive Disorder

About this section

Pathways related to Obsessive-Compulsive Disorder according to KEGG:

36
# Name Kegg Source Accession
1 Serotonergic synapse hsa04726
2 Dopaminergic synapse hsa04728
3 Glutamatergic synapse hsa04724

Pathways related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Circadian entrainment 36
Show member pathways
 12.65 SLC6A3 SLC1A1 MAOA DRD4 DRD3 DRD2
2
cAMP signaling pathway 36
12.21 OXT HTR1B HTR1A DRD2 BDNF
4
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.01 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
5
Amphetamine addiction 36
Show member pathways
 11.87 SLC6A3 MAOA DRD2 BDNF
6
Monoamine GPCRs 1
Show member pathways
 11.84 HTR2A HTR1B HTR1A DRD4 DRD3 DRD2
7
Serotonergic synapse 36
11.76 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1B
8
GPCRs, Other 1
11.72 HTR2A DRD4 DRD3
9
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 60
Show member pathways
 11.7 DRD4 DRD3 DRD2
10
Monoamine Transport 1
Show member pathways
 11.34 TPH2 SLC6A4 SLC6A3 MAOA
11
Neurotransmitter Clearance In The Synaptic Cleft 65
Show member pathways
 11.07 SLC6A4 SLC6A3 MAOA COMT
12
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.95 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1B
13
noradrenaline and adrenaline degradation 1
Show member pathways
 10.75 MAOA COMT
14
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.68 TPH2 SLC6A4 SLC6A3 MAOA HTR1B HTR1A
15
Dopamine metabolism 1
10.66 MAOA COMT
Sources

GO Terms for Obsessive-Compulsive Disorder

About this section

Cellular components related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.32 SLITRK1 SLC6A4 SLC6A3 SLC1A1 SGCE MAOA
2 plasma membrane GO:0005886 10.31 SLITRK1 SLC6A4 SLC6A3 SLC1A1 SGCE HTR3A
3 integral component of plasma membrane GO:0005887 10 SLC6A4 SLC6A3 SLC1A1 SGCE HTR3A HTR2A
4 synapse GO:0045202 9.97 SLITRK1 SLC6A4 SLC1A1 HTR3A HTR2A HTR1A
5 neuron projection GO:0043005 9.91 TPH2 SLC6A4 SLC6A3 SLC1A1 HTR3A
6 glutamatergic synapse GO:0098978 9.91 SLITRK1 HTR3A HTR2A DRD4 DRD3 DRD2
7 axon GO:0030424 9.87 SLC6A3 SLC1A1 HTR3A HTR2A DRD2 COMT
8 GABA-ergic synapse GO:0098982 9.7 SLITRK1 DRD3 DRD2
9 dendrite GO:0030425 9.61 SLC1A1 SGCE HTR2A HTR1B HTR1A DRD4
10 dopaminergic synapse GO:0098691 9.58 SLC6A3 DRD3 DRD2
11 integral component of postsynaptic membrane GO:0099055 9.55 SLC6A4 SLC6A3 HTR3A HTR2A DRD2
12 serotonergic synapse GO:0099154 9.46 SLC6A4 HTR1B
13 integral component of presynaptic membrane GO:0099056 9.1 SLC6A4 SLC6A3 HTR3A HTR2A HTR1B DRD2

Biological processes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.34 OXT HTR3A HTR2A HTR1B HTR1A DRD4
2 G protein-coupled receptor signaling pathway GO:0007186 10.24 OXT HTR2A HTR1B HTR1A DRD4 DRD3
3 chemical synaptic transmission GO:0007268 9.97 SLC1A1 HTR3A HTR2A HTR1B HTR1A DRD4
4 memory GO:0007613 9.94 SLC6A4 OXT HTR2A BDNF
5 cellular calcium ion homeostasis GO:0006874 9.91 HTR2A DRD4 DRD3
6 response to toxic substance GO:0009636 9.91 SLC6A4 DRD3 DRD2
7 locomotory behavior GO:0007626 9.9 SLC6A3 DRD3 DRD2
8 circadian rhythm GO:0007623 9.9 TPH2 SLC6A4 BDNF
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.89 HTR2A HTR1B HTR1A DRD4
10 synapse assembly GO:0007416 9.88 SLITRK1 DRD2 BDNF
11 response to ethanol GO:0045471 9.88 SLC6A3 HTR3A HTR1B DRD3 DRD2
12 positive regulation of synapse assembly GO:0051965 9.87 SLITRK1 OXT BDNF
13 regulation of synaptic vesicle exocytosis GO:2000300 9.87 HTR2A HTR1B DRD2
14 social behavior GO:0035176 9.87 SLC6A4 OXT DRD4 DRD3
15 feeding behavior GO:0007631 9.85 HTR1B DRD2 BDNF
16 behavioral fear response GO:0001662 9.83 HTR1A DRD4 BDNF
17 negative regulation of blood pressure GO:0045776 9.83 OXT DRD3 DRD2
18 negative regulation of protein secretion GO:0050709 9.82 DRD4 DRD3 DRD2
19 arachidonic acid secretion GO:0050482 9.82 DRD4 DRD3 DRD2
20 dopamine receptor signaling pathway GO:0007212 9.81 DRD4 DRD3 DRD2
21 synaptic transmission, dopaminergic GO:0001963 9.8 DRD4 DRD3 DRD2
22 vasoconstriction GO:0042310 9.8 SLC6A4 HTR1B HTR1A
23 negative regulation of voltage-gated calcium channel activity GO:1901386 9.79 DRD4 DRD3 DRD2
24 prepulse inhibition GO:0060134 9.79 SLC6A3 DRD3 DRD2
25 behavioral response to ethanol GO:0048149 9.78 DRD4 DRD3 DRD2
26 behavior GO:0007610 9.77 HTR2A HTR1B HTR1A
27 positive regulation of renal sodium excretion GO:0035815 9.76 OXT DRD3 DRD2
28 response to amphetamine GO:0001975 9.76 OXT DRD4 DRD3 DRD2
29 G protein-coupled receptor internalization GO:0002031 9.75 HTR1B DRD3 DRD2
30 response to iron ion GO:0010039 9.74 SLC6A3 DRD2
31 negative regulation of cytosolic calcium ion concentration GO:0051481 9.74 DRD3 DRD2
32 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 DRD3 DRD2
33 neurotransmitter biosynthetic process GO:0042136 9.73 SLC6A4 SLC6A3
34 grooming behavior GO:0007625 9.73 OXT DRD2
35 regulation of dopamine metabolic process GO:0042053 9.73 SLC6A3 HTR1A DRD4
36 regulation of dopamine secretion GO:0014059 9.73 HTR2A HTR1B DRD3 DRD2
37 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.72 DRD4 DRD3
38 sleep GO:0030431 9.72 OXT HTR2A
39 catecholamine metabolic process GO:0006584 9.72 MAOA COMT
40 inhibitory postsynaptic potential GO:0060080 9.72 DRD4 BDNF
41 regulation of potassium ion transport GO:0043266 9.72 DRD3 DRD2
42 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.72 DRD4 DRD3 DRD2
43 regulation of behavior GO:0050795 9.71 HTR1B HTR1A
44 neurotransmitter catabolic process GO:0042135 9.71 MAOA COMT
45 adenohypophysis development GO:0021984 9.71 SLC6A3 DRD2
46 monoamine transport GO:0015844 9.71 SLC6A4 SLC6A3
47 dopamine catabolic process GO:0042420 9.71 SLC6A3 MAOA COMT
48 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.71 HTR2A HTR1B HTR1A DRD4
49 hyaloid vascular plexus regression GO:1990384 9.7 SLC6A3 DRD2
50 negative regulation of synaptic transmission, GABAergic GO:0032229 9.7 HTR1B BDNF

Molecular functions related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.93 HTR2A HTR1B HTR1A DRD4 DRD3 DRD2
2 G protein-coupled serotonin receptor activity GO:0004993 9.67 HTR2A HTR1B HTR1A DRD4
3 symporter activity GO:0015293 9.65 SLC6A4 SLC6A3 SLC1A1
4 neurotransmitter receptor activity GO:0030594 9.65 HTR3A HTR2A HTR1B HTR1A DRD4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.58 DRD4 DRD3 DRD2
6 dopamine neurotransmitter receptor activity GO:0004952 9.5 DRD4 DRD3 DRD2
7 adrenergic receptor activity GO:0004935 9.49 DRD3 DRD2
8 dopamine binding GO:0035240 9.46 SLC6A3 DRD4 DRD3 DRD2
9 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A4 SLC6A3
10 drug binding GO:0008144 9.43 SLC6A3 HTR2A HTR1B DRD4 DRD3 DRD2
11 serotonin binding GO:0051378 9.02 SLC6A4 HTR3A HTR2A HTR1B HTR1A
Sources

Sources for Obsessive-Compulsive Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....